Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 18/20 | 0.46 |
| ▸ | HTR2C | P28335 | 14/20 | 0.46 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244379 | 0.97 | CHEK2 (0.49) | HTR2AHTR2CCHEK2 | |
| SCHEMBL4126600 | 0.85 | HTR2A (0.41) | HTR2AHTR2C | |
| SCHEMBL5243786 | 0.84 | HTR2A (0.56) | HTR2AHTR2C | |
| SCHEMBL5243616 | 0.83 | HTR2A (0.60) | HTR2AHTR2C | |
| SCHEMBL5247466 | 0.83 | HTR2A (0.47) | HTR2AHTR2CCHEK2 | |
| SCHEMBL5243165 | 0.83 | HTR2A (0.47) | HTR2AHTR2CCHEK2 | |
| SCHEMBL3952777 | 0.83 | HTR2A (0.41) | HTR2AHTR2C | |
| SCHEMBL5246093 | 0.82 | HTR2A (0.60) | HTR2AHTR2C | |
| SCHEMBL4695188 | 0.81 | HTR2A (0.64) | HTR2AHTR2C | |
| SCHEMBL5245210 | 0.81 | HTR2A (0.55) | HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1833799-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT-2a SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006055734-A2 | 3-PHENYL-PYRAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |